盐酸丁咯地尔加用依达拉奉治疗急性脑梗死临床分析

THE CLINICAL EVALUATION OF EDARAVONE AND BUFLOMEDIL IN THE TREATMENT OF ACUTE CEREBRAL INFARCTION

目的观察盐酸丁咯地尔加用依达拉奉治疗急性脑梗死(acute cerebral infarction,ACI)的有效性和安全性。方法采用随机对照试验,将160例ACI患者随机分为治疗组79例和对照组81例,2组均予常规治疗,治疗组给予依达拉奉注射液30mg静脉滴注,2次/d,共14d,同时给予盐酸丁咯地尔150mg加入生理盐水250mL静脉滴注,1次/d,连用14d;对照组仅给予盐酸丁咯地尔150mg加入生理盐水250mL静脉滴注,1次/d,连用14d。结果治疗组总显效率为72.15%,明显优于对照组的46.91%,且无明显不良反应。神经功能缺损评分减少程度治疗组亦明显优于对照组(P<0.05)。结论盐酸丁咯地尔加用依达拉奉联合治疗ACI临床观察疗效满意,可明显改善预后,提高患者的生活质量,是一种安全有效的联合治疗方法。

Objective To evaluate the efficacy and safety of edaravone and buflomedil in the treatment of acute cerebral infarction （ACI）. Methods A totle of 160 patients with ACI were randomly divided into treatment group （ n = 79） and control group （ n = 81 ）. Edaravone was given by intravenous drip at a dose of 30mg, twice a day, for 14 days. Meanwhile, buflomedil was given by intravenous drip at a dose of 150rag, once a day, for 14 days also. The control group was treated only with buflomedil. Results The total effective rate was significantly higher in the treatment group than in the control group. There was no obvious side effect in treatment group. Conclusion Edaravone combined with buflomedil is an effective regimen in the treatment of ACI without obvious side effect.